EUCTR2009-011445-13-BE
Active, not recruiting
Phase 1
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer
Institut Jules Bordet-Université Libre de Bruxelles0 sites225 target enrollmentSeptember 10, 2009
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Stage III colon adenocarcinoma
- Sponsor
- Institut Jules Bordet-Université Libre de Bruxelles
- Enrollment
- 225
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\* Age 18 years or older
- •\* Clinical/radiological evaluation compatible with stage III colon adenocarcinoma
- •\*No prior chemotherapy
- •\* No prior abdominal or pelvic irradiation
- •\*WHO performance status 0 or 1
- •\*Effective contraception during the study and the following six months
- •\*Signed informed consent obtained prior to any study\-specific screening procedures
- •\*Tumour considered as curatively resectable (R0\) based on standard preoperative evaluations
- •\*White blood cell count \= 3×109/L with neutrophils \= 1\.5×109/L, platelet count \= 100×109/L, haemoglobin \= 9 g/dL (5\.6 mmol/L)
- •\*Direct bilirubin \= 1\.5×ULN; ASAT and ALAT \= 2\.5×ULN; Alkaline phosphatase \= 2\.5×ULN; Serum creatinine \= 1\.5×ULN
Exclusion Criteria
- •\*Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to screening. Incompletely healed wounds or anticipation of the need for major surgical procedure during the course of the study
- •\*Any suspicion of metastatic disease
- •\*Rectal cancer located within 15 cm from the anal verge by endoscopy or under the peritoneal reflection at surgery
- •\*Inflammatory bowel disease
- •\*Pregnancy (absence to be confirmed by ß\-hCG blood test) or breast\-feeding
- •\*History or current central nervous system disease or peripheral neuropathy
- •\*Hypersensitivity to any of the components of study treatments
- •\* Previous malignancy in the last five years except basal\-cell carcinoma of the skin or in situ cervical carcinoma
- •\*Clinically relevant coronary artery disease or history of myocardial infarction in the last 6 weeks or high risk of uncontrolled arrhythmia
- •\*Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon CancerColon CancerNCT00994864Jules Bordet Institute235
Recruiting
Not Applicable
Preoperative Biomarkers as Prognostic Factors for Postoperative Upgrading in Prostate CancerC61Malignant neoplasm of prostateDRKS00034653Klinikum der Universität München8,000
Not yet recruiting
Phase 2
Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: Multicentric Phase II Study2024-517183-31-00Centro Di Riferimento Oncologico Di Aviano93
Completed
Not Applicable
A phase II study of preoperative chemotherapy cosisting docetaxel, oxaliplatin and S-1 for the clinical Stage III gastric cancerGastric cancerJPRN-UMIN000017652Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine50
Recruiting
Not Applicable
Feasibility and efficacy of preoperative chemoradiation and postoperative liver perfusion chemotherapy for T3 (UICC) pancreatic cancerJPRN-UMIN000001804Osaka Medical Center for cancer & Cardiovascular Diseases gastrointestinal & hepatobiliary- pancreatic surger300